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Abstract
Methicillin-sensitive Staphylococcus aureus (MSSA) is susceptible to many beta-lactams. We compared cloxacillin and cefazolin, the ﬁrst-
line recommended antibiotics, and other beta-lactams in the treatment of MSSA bacteraemia. This was a retrospective cohort study.
Included were adult patients with clinically-signiﬁcant MSSA bacteraemia treated with a beta-lactam that was started within 48 h after
blood cultures were taken. We separated between empirical treatment administered to the patient before receipt of ﬁnal blood culture
results and deﬁnitive treatment administered thereafter. Univariate and multivariable analyses for 30-day (empirical treatment) and 90-
day (deﬁnitive treatment) mortality were conducted, including the type of beta-lactam administered to the patient. Five-hundred and
forty-one patients were included for the analysis of empirical treatment and 498 patients alive at 7 days were evaluable for deﬁnitive
treatment. Empirical treatment with cloxacillin or cefazolin (n = 131) was associated with lower 30-day mortality as compared with
cefuroxime (n = 98, p 0.058), ceftriaxone or cefotaxime (n = 194, p 0.008) and beta-lactam-beta-lactamase combinations (n = 61,
p 0.013), with adjusted odds ratios (OR) for death ranging from 1.98 to 2.68. Deﬁnitive treatment with cefazolin (n = 72) was not signif-
icantly different from cloxacillin (n = 281); adjusted OR for 90-day mortality 0.91 (95% conﬁdence interval 0.47–1.77). Treatment with
cefazolin both in the empirical and deﬁnitive periods was not signiﬁcantly different from cloxacillin; adjusted OR 0.81 (95% conﬁdence
interval 0.18–3.62). Treatment of MSSA bacteraemia with cefazolin is not signiﬁcantly different from treatment with cloxacillin, while
treatment with other beta-lactams, including second and third generation cephalosporins, might be associated with higher mortality.
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Background
Beta-lactamase-producing strains of methicillin-sensitive
Staphylococcus aureus (MSSA) are preferably treated with a
semi-synthetic penicillin (e.g. nafcillin or oxacillin). A ﬁrst-
generation cephalosporin is an alternative [1]. Whether
penicillins or cefazolins are more efﬁcacious is unknown.
Other beta-lactams provide coverage against MSSA; how-
ever, they do not appear in recommendations for treat-
ment and their clinical efﬁcacy against invasive MSSA
infections is unclear.
It is a common clinical scenario to face a patient coming
from the community with severe sepsis and suspected
staphylococcal infection. In locations where community-
acquired MRSA is not endemic, the physician would
debate whether to use a beta-lactam speciﬁc for MSSA, a
broader-spectrum beta-lactam (e.g. ceftriaxone), which
would cover Gram-negative bacteria as well, or both. After
identiﬁcation of MSSA, the main dilemma is between
oxacillin (or another penicillin) and cefazolin, although we
do not know whether other beta-lactams provide similar
efﬁcacy.
The optimal design for comparing beta-lactams in the
treatment of invasive staphylococcal infections is a random-
ized controlled trial. Such a trial is difﬁcult to conduct
and has not been performed to date. We compared out-
comes for patients given different beta-lactams for the
treatment of MSSA bacteraemia in a retrospective cohort
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study, attempting to adjust for the differences between
patients treated with narrow vs. broad-spectrum
beta-lactams.
Methods
Design
This was a retrospective cohort study. The study was
approved by the local ethics committee.
Setting
The study was carried out at the Rabin Medical Center, Beil-
inson Hospital. Data were collected between 1988–1994 and
1999–2007.
Participants
Patients with growth of MSSA in blood were identiﬁed
through the microbiology laboratory records. Data were col-
lected for all patients in whom MSSA was identiﬁed at least
in two separate sets of blood cultures or those who fulﬁlled
criteria for systemic inﬂammatory response syndrome within
48 h of a positive blood culture with no other source of
infection. Repeat episodes were included only with an inter-
val of 1 year or more between episodes. Cases of polymicro-
bial bacteraemia were excluded, unless appropriate antibiotic
treatment for the co-pathogen was instituted empirically.
We included in the current analysis only patients treated
with a beta-lactam antibiotic that was started within 48 h
after collection of positive blood cultures (e.g. appropriate
empirical and deﬁnitive antibiotic treatment). Referring to
the clinical questions, we classiﬁed empirical treatment into
ﬁve categories: cloxacillin, penicillin if susceptible or cefazolin;
cefuroxime; ceftriaxone or cefotaxime; beta-lactam-beta-lac-
tamase combinations; and other beta-lactams (other cephalo-
sporins and carbapenems). Deﬁnitive treatment was classiﬁed
into three categories: cloxacillin/penicillin; cefazolin; and
other beta-lactams. A subgroup analysis of deﬁnitive treat-
ment was conducted restricted to patients who received the
same empirical and deﬁnitive treatment.
Treatment given to the patient during the ﬁrst 2 days
after collection of blood cultures was recorded as the empir-
ical treatment and that given on days 3–9 (ﬁrst week after
receipt of blood culture results) was recorded as deﬁnitive
treatment. We did not consider further treatment, because
it might have been inﬂuenced by patients’ responses to previ-
ous treatment (clinical failure, success or persistence of bac-
teraemia). The analysis of deﬁnitive treatment was restricted
to patients alive at day 7. All patients are included in the
analysis of empirical antibiotic treatment.
Variables
The outcome considered was 30-day all-cause mortality for
empirical antibiotic treatment. For deﬁnitive treatment, we
assessed 90-day mortality, as in previous studies [2,3], con-
sidering that the deﬁnitive antibiotic regimen was usually
continued for 2–4 weeks. To examine risk factors for death
and to compare between study groups we collected a large
dataset of variables pertaining to patient demography (includ-
ing place of infection acquisition and functional status), back-
ground conditions, risk factors speciﬁc for staphylococcal
bacteraemia (indwelling catheters and other devices, invasive
procedures, etc.), clinical presentation, source of bacteraemia
and severity of sepsis, laboratory measurements on the day
of blood culture collection and infection management (includ-
ing removal of foreign devices). All data were obtained
through patient chart review and the electronic hospital
records. Mortality data were derived from the Israeli Internal
Ministry registry. Hospital-acquired infection was deﬁned
when blood cultures were taken 48 h or more after admis-
sion and healthcare-associated infections were deﬁned as
previously suggested [4]. All antibiotic treatment from the
date of blood culture collection until 30 days was recorded.
Microbiology
Staphylococci were identiﬁed using the Slidex-Staph Kit (bio-
Merieux, France), the Pastorex Staph (Sanoﬁ Diagnostics,
Pasteur) slide agglutination test conﬁrmed by DNase or the
API-Staph test (bioMerieux, France). Antibiotic susceptibility
was tested using the disk diffusion method on Mueller–Hin-
ton agar, according to contemporaneous NCCLS or CLSI
standards. We considered all beta-lactam-beta-lactamase
combinations, cephalosporins and carbapenems as covering,
regardless of susceptibility testing. Penicillin derivatives (e.g.
piperacillin and mezlocillin) were considered covering only if
the isolate was susceptible to penicillin or if the antibiotic
was tested and found covering.
Statistical analysis
To identify the risk factors for death we compared dichoto-
mous variables using a chi-square test and continuous vari-
ables using a t-test or the Mann–Whitney U-test, as
appropriate. To exclude variables with high co-linearity from
the multivariate analysis, variables signiﬁcantly associated with
30-day mortality on univariate analysis were assessed for
bivariate correlation using Spearman’s q test. We excluded
from further analysis signiﬁcantly correlated variables
(p <0.001 and R between 0.26 and 0.71), selecting the more
clinically relevant variable in correlated pairs. Selected vari-
ables were entered as covariates into a conditional forward
1582 Clinical Microbiology and Infection, Volume 17 Number 10, October 2011 CMI
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1581–1586
stepwise logistic regression analysis for 30-day mortality for
empirical and deﬁnitive treatment. The type of beta-lactam
was forced into each model. Odds ratios (ORs) with 95%
conﬁdence intervals (CIs) are reported. The ﬁt of the model
was tested using the Hosmer-Lemeshow goodness of ﬁt test
and its prediction using the area under the ROC curve
(AUC) generated by predicted probabilities. Analyses were
conducted using PASW statistics 17.0 (SPSS, Inc).
Results
Out of 771 clinically signiﬁcant episodes of MSSA bacteraemia,
541 episodes could be evaluated for empirical treatment and
498 patients alive on day 7 were evaluated for deﬁnitive treat-
ment (Fig. 1). Patient characteristics are detailed in Table 1.
Infections were rarely acquired in the community without
contact with the healthcare setting. More than 50% of patients
died within 1 year following the bacteraemia.
There were signiﬁcant differences in baseline patient char-
acteristics between patients treated empirically with targeted
therapy against MSSA (oxacillin or cefazolin) and those given
broader-spectrum beta-lactams (data not shown). Mortality
at 30 days without adjustment for these differences was
22.1% (29/131) for empirical treatment with cloxacillin or
cefazolin compared with 34.7% (34/98) with cefuroxime,
50.5% (98/194) with ceftriaxone/cefotaxime, 41% (25/61) with
beta-lactam-beta-lactamase combinations and 28.1% (16/57)
with other beta-lactams (p <0.001 overall). Empirical treat-
ment with vancomycin was not associated with 30-day
mortality [32/82 (39%) with vancomycin vs. 170/459 (37%)
without vancomycin combination therapy, p 0.732]. In the
adjusted analysis for empirical antibiotic treatment, beta-lac-
tams other than cloxacillin or cefazolin were associated with
higher 30-day mortality (Table 2). The adjusted OR for
empirical treatment with cefuroxime was 1.98 (95% CI 0.98–
4.01), for ceftriaxone or cefotaxime 2.24 (95% CI 1.23–4.08)
and for beta-lactam-beta-lactamase combinations 2.68 (95%
CI 1.23–5.85). For other beta-lactams (mainly ceftazidime)
mortality was not signiﬁcantly different from cloxacillin/cefaz-
olin, but most patients were treated in combination with
vancomycin and conﬁdence intervals were wide. Other risk
factors for 30-day mortality are shown in Table 2. The mod-
el’s calibration and predictive performance were adequate.
Considering deﬁnitive antibiotic treatment, there were no
statistically signiﬁcant differences in 90-day mortality with dif-
ferent beta-lactams in the unadjusted analysis: 32.4% (91/281)
with cloxacillin, 40.3% (29/72) with cefazolin and 42.1% (61/
145) with other beta-lactams. There was no signiﬁcant differ-
ence in 90-day mortality between deﬁnitive treatment with
cefazolin vs. cloxacillin in the adjusted analysis; OR 0.91 for
all 498 patients evaluated and OR 0.81 for the subgroup of
204 patients treated with cefazolin or cloxacillin both empiri-
cally and deﬁnitively (Table 3). Mortality was higher with
other beta-lactams (OR 1.29, 95% CI 0.77–2.14 overall, and
OR 1.64, 95% CI 0.79–3.38 for the subgroup analysis), but
Clinically-significant MSSA 
bacteraemia episodes, n = 771
Polymicrobical bacteraemias 
excluded, n = 35 
Empirical treatment not considered: 
Inappropriate/ no treatment, n = 91 
Vancomycin, n = 61 
Quinolone, n = 33 
Other appropriate, n = 10 
Eligible episodes, n = 736 
Episodes analysed (n = 541) by empirical 
treatment:1
1. Cloxacillin/penicillin, n = 103 + cefazolin, n = 28 
2. Cefuroxime, n = 98 
3. Ceftriaxone, n = 176 + cefotaxime, n = 18 
4. Piperacillin-tazobactm, n = 32 + ampicillin-
clavulanate, n = 28, ampicillin-sulbactam, n = 1 
5. Ceftazidime, n = 49 + carbapenem, n = 7 + 
cefepime, n = 1
Deaths during first week excluded, 
n = 120 
Definitive treatment not considered: 
Inappropriate/missing data, n = 16 
Vancomycin, n = 57 
Quinolone, n = 29 
Other appropriate, n = 16 
Episodes analysed (n = 498) by definitive 
treatment: 
1. Cloxacillin, n = 281 
2. Cefazolin, n = 72 
3. Other beta-lactams, n = 145 
(ceftriaxone/ cefotaxime, n = 42 + 
cefuroxime, n = 42 + beta-lactam-beta 
lactamse inhibitor, n = 34 + ceftazidime, 
n = 16 + carbapenem, n = 8 + cefepime, n = 3)
FIG. 1. Patient selection. 1Vancomycin was
administered empirically together with the
beta-lactam in 9/131 (6.9%) patients in group
1; 0% in group 2; 23/194 (11.9%) in group 3;
16/61 (26.2%) in group 4 and 34/57 (59.6%)
patients in group 5.
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the differences were not statistically signiﬁcant. Fewer vari-
ables could be assessed in the model for patients treated
with the same beta-lactam empirically and deﬁnitively
(Table 3), although both models retained adequate predictive
performance, with similar results.
Discussion
We compared different beta-lactams in the treatment of
MSSA bacteraemia. Addressing different clinical scenarios we
separated the empirical treatment phase (ﬁrst 48 h, before
receipt of ﬁnal blood culture results and susceptibilities) and
deﬁnitive antibiotic treatment (administered thereafter).
Empirical treatment with beta-lactams other than cloxacillin
or cefazolin was associated with higher 30-day mortality com-
pared with treatment with these recommended antibiotics.
Speciﬁcally, third generation cephalosporins (ceftriaxone and
cefotaxime) and beta-lactam-beta-lactamase combinations
were associated with more than double the odds for death,
adjusted to other risk factors for mortality. The main compar-
ison of deﬁnitive antibiotic treatment was between cloxacillin
and cefazolin. There was no signiﬁcant difference between
them in 90-day mortality; adjusted OR 0.91, 95% CI 0.47–
1.77. The data for other beta-lactams in the deﬁnitive phase
were too sparse for assessment of their effects on mortality.
Previous studies have established the superiority of beta-
lactam treatment over glycopeptides for MSSA [2,3,5–8]. In
most of these studies any beta-lactam was considered as
adequate treatment for MSSA and compared with vanco-
mycin. Two studies speciﬁcally assessed cloxacillin [8] and
cefazolin [3]. Advantage of the beta-lactam was reported by
all studies but it is difﬁcult to compare their results because
of the different outcomes reported (bacteraemia persistence,
relapse, infection-related mortality, etc.). Direct comparisons
between different beta-lactams are scarce. In-vitro, it has been
reported that penicillinase-resistant penicillins were more
resistant to the inoculum effect and to staphylococcal beta-
lactamase than ﬁrst-generation cephalosporins, suggesting
better efﬁcacy of the former [9]. Wynn et al. compared dif-
ferent antibiotics given as outpatient parenteral antimicrobial
therapy (OPAT) for various MSSA infections, including the
beta-lactams ceftriaxone, cefazolin, oxacillin and nafcillin. In
TABLE 1. Patient characteristics
Variable
n/541 (%) unless
otherwise noted
Age (years), mean (SD) 69 (16.8)
Female sex 243 (44.9)
Admitted from home 392/505 (72.5)
Functional capacity
Independent 295 (54.5)
Assistance in daily activities 114 (21.1)
Bedridden 132 (24.4)
Place of infection acquisitiona
Community 66 (12.2)
Healthcare associated 207 (38.3)
Hospital 268 (49.5)
Previous antibiotic treatment within 30 days 230 (42.5)
Hospitalization department
Medical 421 (77.8)
Surgical 92 (17)
ICU 28 (5.2)
Diabetes 168 (31.1)
Malignancy 152 (28.1)
Chronic renal failure 122 (22.6)
Haemodialysis 21 (3.9)
Congestive heart failure 86 (15.9)
Valvular heart diseaseb 62 (11.5)
Surgery 30 days before infection 108 (20)
Shock at onset of infection 66 (12.2)
Number of positive blood culture bottles >4 82/415 (19.8)
Polymicrobial bacteraemia 41 (7.6)
Source of infection
Skin/soft tissue 83 (15.3)
Surgical wound infection 49 (9.1)
Bone or joint 27 (5)
Endocarditis 25 (6.5)
Catheter-related 63 (11.6)
Other endovascular 41 (7.6)
Pneumonia 54 (10)
Other documented sourcec 25 (4.6)
Primary/unknown 122 (22.6)
Persistence of bacteraemia >5 days 46 (8.5)
Relapse of bacteraemia within 1 year 12 (2.2)
Mortality at 48 h 52 (9.6)
Mortality at 30 days 202 (37.3)
Mortality at 90 days 266 (49.2)
Mortality at 1 year 315 (58.2)
aBacteraemia was considered hospital acquired when blood cultures were taken
more than 48 h after admission. Healthcare acquisition was deﬁned for: patients
receiving intravenous therapy, chemotherapy, haemodialysis, wound care or spe-
cialized nursing care, or those who attended a hospital clinic within 30 days
before bacteraemia; patients hospitalized in an acute care hospital ‡2 days
within 90 days; or those residing in a nursing home or long-term care facility.
bIncluding prosthetic valve in 32 patients.
cOther sources of infection included abdominal, central nervous system and
abscesses.
TABLE 2. Multivariable logistic regression analysis for 30-
day mortality: empirical antibiotic treatmenta
Variableb
OR, 95% CI
n = 541 patients,
deaths = 202 p-value
Empirical antibiotic treatment
Oxacillin/cefazolin Reference
Cefuroxime 1.98 (0.98–4.01) 0.058
Ceftriaxone/cefotaxime 2.24 (1.23–4.08) 0.008
Beta-lactam-beta-lactamase 2.68 (1.23–5.85) 0.013
Other beta-lactams 0.81 (0.35–1.9) 0.629
Age (per 1 year increment) 1.04 (1.02–1.06) <0.001
Female sex 1.69 (1.08–2.63) 0.021
Poor functional capacity (bedridden) 1.73 (1.02–2.93) 0.041
Malignancy 1.89 (1.15–3.09) 0.012
Shock at onset 5.61 (2.75–11.45) <0.001
Urea (per 1 mg/dL increment) 1.01 (1.007–1.016) <0.001
Albumin (per 1 mg/dL increment) 0.54 (0.38–0.78) 0.001
Thrombocytes (per 1 K/lL increment) 0.996 (0.994–0.998) <0.001
Mechanical ventilation Not retained in ﬁnal model 0.078
Skin/soft tissue source of infection 0.111
aSigniﬁcance of the model’s constant p 0.004, Hosmer and Lemeshow, p 0.71,
area under ROC curve for model’s prediction of 30-day mortality 0.84 (95% CI
0.81–0.88), p <0.001.
bThe following variables were signiﬁcantly associated with mortality on univari-
ate analysis, but not used in the multivariable analysis due to signiﬁcant correla-
tion with other included variables: MSSA isolation in specimens other than
blood cultures, urinary catheter, recent surgery, use of corticosteroids before
onset of infection, chronic renal failure, congestive heart failure, dementia and
primary source of infection. CI, conﬁdence interval; OR, odds ratio.
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the OPAT setting cephalosporins might offer an advantage
due to a more convenient administration schedule. No dif-
ferences were observed in the outcome ‘Did the clinical out-
come meet expectations?’ and with regard to adverse events
necessitating treatment discontinuation. Only a few patients
with bacteraemia were assessed in each of the beta-lactam
categories (11–17 patients) [10]. A small study described
similar mortality for MSSA meningitis treated with ce-
furoxime compared with penicillins [11]. We are not aware
of a randomized controlled trial comparing different beta-lac-
tams in the treatment of MSSA infections.
The main limitation of the present analysis is that treatment
selected by clinicians was confounded by underlying patient
characteristics. Probably no method can fully adjust for the dif-
ferences between patients given cloxacillin or cefazolin empiri-
cally and those treated with broader spectrum beta-lactams.
We attempted to adjust for these differences using multivari-
able regression analysis. While the model constructed was
highly predictive, we cannot be sure that all differences
between patients treated with narrow vs. broad-spectrum
beta-lactams were adjusted for. Once MSSA is identiﬁed, a
comparison between cloxacillin and cefazolin is more valid,
because there is no information regarding whether one or the
other treatment is superior. However, this analysis was limited
by the paucity of patients treated with cefazolin, resulting in
wide conﬁdence intervals. We limited the analysis of deﬁnitive
antibiotic treatment to the ﬁrst week because treatment mod-
iﬁcations after this period were frequently dictated by
patients’ responses to the initial treatment regimen. For simi-
lar reasons we did not consider the overall treatment duration
and antibiotic combinations with aminoglycosides and rifam-
pin. Combination treatment is rare in our centre because
there is no evidence for its effect on survival [12,13] and com-
bination treatment did not signiﬁcantly affect survival in this
cohort (data not shown). A distinctive feature of our cohort
was that truly community-acquired bacteraemias were rare
(12.2%). We used contemporaneous deﬁnitions for health-
care-associated bacteraemia and our electronic healthcare sys-
tem allows for a very high precision in identifying patients’
exposure to the healthcare system before hospitalization.
In summary, we present the ﬁrst analysis attempting to
compare different beta-lactams in the treatment of MSSA
bacteraemia. Empirical treatment with oxacillin or cefazolin
was associated with lower 30-day mortality than other beta-
lactams. Deﬁnitive treatment with cefazolin or cloxacillin
resulted in similar 90-day mortality rates. These results are
severely hampered by the association between the treatment
regimen selected by clinicians and underlying patient charac-
teristics. This study highlights the difﬁculties in comparing
treatments in a non-randomized design. Many questions
regarding the treatment of invasive S. aureus infections in
general and MSSA bacteraemia in particular exist, including
the type of antibiotic, combination therapy and duration of
treatment. These questions should be answered in random-
ized controlled trials.
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TABLE 3. Multivariable logistic regression analysis for 90-day mortality: deﬁnitive antibiotic treatment
Variable All deﬁnitive n = 498, deaths = 181a Subgroup deﬁnitive n = 204,
deaths = 71b
Variablec OR (95% CI) p-value OR (95% CI) p-value
Deﬁnitive antibiotic treatment
Oxacillin Reference Reference
Cefazolin 0.91 (0.47–1.77) 0.781 0.81 (0.18–3.62) 0.782
Other beta-lactam 1.29 (0.77–2.14) 0.332 1.64 (0.79–3.38) 0.184
Age (per 1-year increment) 1.05 (1.03–1.07) <0.001 1.04 (1.01–1.06) 0.004
Poor functional capacity (bedridden) 2.33 (1.31–4.13) 0.004 Not included
Hospital-acquired bacteraemia 2.3 (1.44–3.67) 0.001 2.26 (1.14–4.47) 0.019
Diabetes 1.8 (1.12–2.9) 0.015 Not included
Malignancy 2.54 (1.51–4.27) <0.001 2.52 (1.18–5.36) 0.017
Valvular heart disease 2.38 (1.22–4.64) 0.011 Not included
Urea (per 1 mg/dL increment) 1.008 (1.003–1.013) 0.001 1.01 (1.002–1.018) 0.018
Albumin (per 1 mg/dL increment) 0.4 (0.27–0.58) <0.001 0.48 (0.27–0.83) 0.008
Thrombocytes (per 1 K/lL increment) 0.997 (0.995–0.999) 0.003 Not included
Shock at onset of infection Not retained in ﬁnal model 0.066 Not included
Mechanical ventilation 0.054 Not included
Primary source of infection 0.058 Not included
aSigniﬁcance of the model’s constant p 0.01, Hosmer and Lemeshow p 0.685, area under ROC curve for model’s prediction of 90-day mortality 0.84 (95% CI 0.80–0.87),
p <0.001.
bSubgroup of patients who received the same empirical and deﬁnitive antibiotic treatment. Signiﬁcance of the model’s constant p 0.059, Hosmer and Lemeshow p 0.616, area
under ROC curve for model’s prediction of 90-day mortality 0.78 (95% CI 0.72–0.85), p <0.001.
cThe following variables were signiﬁcantly associated with mortality on univariate analysis, but not used in the multivariable analysis due to signiﬁcant correlation with other
included variables: urinary catheter, chemotherapy, chronic renal failure, congestive heart failure, dementia and presence of a foreign body. CI, conﬁdence interval; OR, odds ratio.
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